Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estado, etc.

1. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

2. A Study to Evaluate the Use of Organoids to Advance Precision Medicine in Bladder Cancer

   Rochester, Minn.

   The purpose of this study is to develop patient-derived organoid cultures of urothelial carcinoma from non-invasively obtained urine samples and to characterize the histological, molecular and functional features of patient-derived organoids.

3. A Study to Evaluate the Immune Response to Anti-HER2 Therapies

   Jacksonville, Fla.

   The purpose of this study is to determine the correlation between HER2 specific T-cell response in HER2-positive breast cancer patients with stage I-IV who receive anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib and clinical responses.

4. Biorepository for Acute Leukemia Research

   Rochester, Minn.

   The purpose of this IRB protocol is to establish a specimen bank for research into acute leukemias. In particular, we plan to bank blood and bone marrow from patients with newly diagnoses or relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to investigate not only the biology of these marrow disorders, but also the changes that occur to render these disorders resistant to therapy. These activities are a first step toward identifying alternative therapies and subsequently beginning to personalize the therapy for these disorders.

5. SULF1 and SULF2 Role in Cholangiocarcinoma

   Rochester, Minn.

   Cholangiocarcinoma (CCA) has key similarities with HCC, therefore, we hypothesize that Sulf1 and Sulf2 may also play roles in promotion of CCA progression.

6. A Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

   Rochester, Minn.

   This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

7. A Study of Prostate Cancer Care and Survivorship Among Sub-Saharan African Immigrant Impacted by Social Determinants of Migrant Health Factors

   Rochester, Minn.

   The primary objective of this study is to employ the social determinant of migrant health framework (International Organization for Migration, n.d.) to examine the impact of immigration on the health-seeking behaviors of Sub-Saharan African Immigrant (SSAI) and Caribbean Immigrant (CI) men including informed-decision making, psychosocial effects and coping mechanisms.  

8. Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to identify the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.

9. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

10. Changes in Blood Components in Patients with Ovarian Cancer

    Rochester, Minn.

    The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer for future research projects to identify changes in levels of various plasma components that occur during the course of ovarian cancer, including changes that occur with debulking surgery, chemotherapy, disease relapse, and subsequent therapy.